All In Biotech

BLA 020772 · Qol Medcl

Sucraid

Sacrosidase · Oral · Sucrose-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Apr 9, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

0 Phase 3, 0 recruiting

FAERS reports

181

30 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 29, 2025.

INDICATIONS AND USAGE Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 9, 1998 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetter
1 products under this application
  • SUCRAID · SACROSIDASE 8,500 IU/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sacrosidase" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea36
  • abdominal pain35
  • drug ineffective22
  • nausea21
  • abdominal distension19
  • flatulence17
  • headache12
  • product quality issue12
  • dizziness11
  • vomiting11
  • fatigue9
  • insomnia9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20132
20143
20152
201635
20171
20186
20193
20202
20212
202212
202331
202437
202525
202619

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sucraid (Sacrosidase)

2024 spending

$108M

Beneficiaries

2,168

8,121 claims

Per beneficiary

$49,659

$38.83 per unit

View as table
YearSpending
2020$37,834,003
2021$46,624,899
2022$53,127,582
2023$77,406,308
2024$107,661,425

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Qol Medcl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.